Pharma — Juni 2022
-
test
-
Lundbeck: Studie af Vyepti publiceres i prestigefyldte The Lancet
https://www.proinvestor.com/investornyt/838454/lundbeck-studie-af-vyepti-publiceres-i-prestigefyldte-the-lancet -
Lundbeck er klar til FDA-ansøgning efter vigtige Alzheimers-data - NY2
https://www.proinvestor.com/investornyt/842756/lundbeck-er-klar-til-fda-ansogning-efter-vigtige-alzheimers-data-ny2 -
ALK igangsætter fase 1-studie med tabletvaccine mod peanutallergi - NY
https://www.proinvestor.com/investornyt/842863/alk-igangsaetter-fase-1-studie-med-tabletvaccine-mod-peanutallergi-ny -
ALK/dir: Peanutvaccine giver god mening - ser godkendelse senest 2030
https://www.proinvestor.com/investornyt/842954/alk-dir-peanutvaccine-giver-god-mening-ser-godkendelse-senest-2030 -
Lundbeck/SEB: Kursmål løftes til 40 kr. - GENT
https://www.proinvestor.com/investornyt/843327/lundbeck-seb-kursmal-loftes-til-40-kr-gent -
Novartis skal fyre 7 pct. af de ansatte
https://www.proinvestor.com/investornyt/843882/novartis-skal-fyre-7-pct-af-de-ansatte
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind